title: Clinical activity of leukotriene inhibitors.
abstract: Data from the emerging clinical trials with compounds such as zileuton, ICI 204,219, Bay X1005, MK571, MK679, and MK591 are demonstrating the importance of the leukotrienes as mediators of asthma and possibly other diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. One of the major questions facing the asthma community is how much improvement in the FEV1 is needed to improve the quality of life of the asthmatic patient. Comparing the various approaches to asthma treatment, there is typically 15-20% improvement in the lung function with inhaled steroids. Leukotriene interventions apparently will improve lung function to similar levels as with inhaled steroids, and thus may offer an alternative to steroids. Like the steroids, zileuton appears to also reduce the inflammatory cell influx into the antigen-challenged site, which may have the long-term effect of reversing some of the tissue alterations that occur as a result of the inflammation seen with asthma. Importantly, the reported experience to date has shown that the leukotriene modulators do not have the same side-effects as the current therapies, and thus offer the hope that both safe and effective treatment may be derived from this approach. The clinical data reported do not yet define a preferred approach to the modulation of leukotriene pathology. As more studies are published in other diseases the broad spectrum use of these inhibitors will become known.
authors.affiliation: Abbott Laboratories, Abbott Park, IL 60064, USA.
authors.forename: R R
authors.initials: RR
authors.lastname: Harris
authors.forename: G W
authors.initials: GW
authors.lastname: Carter
authors.forename: R L
authors.initials: RL
authors.lastname: Bell
authors.forename: J L
authors.initials: JL
authors.lastname: Moore
authors.forename: D W
authors.initials: DW
authors.lastname: Brooks
mesh_terms: D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy* / Q000209:etiology; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D020024:Leukotriene Antagonists; D015289:Leukotrienes / Q000502:physiology / Q000627:therapeutic use*; D016859:Lipoxygenase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D008297:Male; D008954:Models, Biological; D011565:Psoriasis / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors